| Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting | 10/01 08:05 | businesswire.com |
| Savara Announces New Employment Inducement Grant | 09/27 16:05 | businesswire.com |
| Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | 09/27 08:05 | businesswire.com |
| Savara to Host Analyst and Investor Webinar on September 30, 2024 | 09/23 08:05 | businesswire.com |
| Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024 | 08/15 08:05 | businesswire.com |
| Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday? | 06/26 09:36 | benzinga.com |
| Savara's rare lung disease drug meets main goal in late-stage study | 06/26 06:41 | reuters.com |
| Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | 06/26 06:30 | businesswire.com |
| Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | 06/25 20:05 | businesswire.com |
| 3 Penny Stocks Poised for Major Upside Over the Next 5 Years | 06/19 09:00 | investorplace.com |